Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fuoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fuoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients
To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs.